段彦龙

Brentuximab vedotin combined with risk-adapted chemoimmunotherapy for Hodgkin’s lymphoma in Chinese children: a single-center, nonrandomized controlled study

Classic Hodgkin lymphoma (cHL) has high curability following chemotherapy combined with radiation treatments, but an excess of short-term and long-term treatment-related morbidities remain a concern. The challenge associated with cHL treatment lie in significantly reducing the lo...